We are live on ! Find out more
PHAR icon

Pharming Group
PHAR

3 hedge funds and large institutions have $245K invested in Pharming Group in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 0.03% → 0.04% (+0.01%)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$42.9K
2
Cowen Prime Advisors
Cowen Prime Advisors
New York
+$2.02K
3
UBS Group
UBS Group
Switzerland
+$626

Top Sellers

No sellers this quarter

PHAR Hedge Fund Activity: Q3 2022 in Review

3 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q3 2022, worth a combined $245K — up 36% from $180K a quarter earlier.

Fund positioning in PHAR was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $42.9K.

  • 3 institutional investors held Pharming Group (PHAR) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $245K of Pharming Group stock for Q3 2022, up 36% quarter-over-quarter.
  • 0 funds opened new Pharming Group positions in Q3 2022 and 0 closed out.
  • The largest Pharming Group buyer in Q3 2022 was Morgan Stanley, an estimated $42.9K added.

Based on aggregated 13F filings for Q3 2022.